Sökning: onr:"swepub:oai:lup.lub.lu.se:e4b653eb-a74e-4ab2-90a2-44bb8f7c55ba" >
Prevention of venou...
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study
-
Alikhan, R (författare)
-
Cohen, AT (författare)
-
Combe, S (författare)
-
visa fler...
-
Samama, MM (författare)
-
Desjardins, L (författare)
-
Eldor, A (författare)
-
Janbon, C (författare)
-
Leizorovicz, A (författare)
-
- Olsson, Carl-Gustav (författare)
- Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine
-
Turpie, AGG (författare)
-
visa färre...
-
(creator_code:org_t)
- 2003
- 2003
- Engelska.
-
Ingår i: Blood Coagulation and Fibrinolysis. - 1473-5733. ; 14:4, s. 341-346
- Relaterad länk:
-
http://www.bloodcoag...
-
visa fler...
-
http://dx.doi.org/10...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- The Medical Patients with Enoxaparin (MEDENOX) trial was a randomized, placebo-controlled study that defined the risk of venous thromboembolism (VTE) in acutely ill, immobilized, general medical patients and the efficacy of the low-molecular-weight heparin, enoxaparin, in preventing thrombosis. We performed a post-hoc analysis to evaluate the effect of 40 mg enoxaparin once daily on MEDENOX patient outcome in different types of acute medical illness (heart failure, respiratory failure, infection, rheumatic disorder and inflammatory bowel disease) and pre-defined risk factors (chronic heart and chronic respiratory failure, age, immobility, previous VTE and cancer). The primary outcome was the occurrence of documented VTE between days 1 and 14. The relative risk reduction [95% confidence intervals (CI)] for VTE comparing 40 mg enoxaparin with placebo in the subgroups were: acute heart failure, 0.29 (95% CI, 0.10-0.84); acute respiratory failure, 0.25 (95% CI, 0.10-0.65); acute infectious disease, 0.28 (95% CI, 0.09-0.81); and acute rheumatic disorder, 0.48 (95% CI, 0.11-2.16). The relative risk reduction for VTE in the pre-defined risk factor subgroups were: chronic heart failure, 0.26 (95% Cl, 0.08-0.92); chronic respiratory failure, 0.26 (95% CI, 0.10-0.68); age, 0.22 (95% CI, 0.09-0.51); immobility, 0.53 (95% CI, 0.14-1.72); previous VTE, 0.49 (95% CI, 0.15-1.68); and cancer, 0.50 (95% CI, 0.14-1.72). The beneficial effects of enoxaparin extend to a wide range of acutely ill medical patients. (C) 2003 Lippincott Williams Wilkins.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- venous thromboembolism
- thromboprophylaxis
- low-molecular-weight heparin
- enoxaparin
- safety
- risk factor
- subgroup
- acutely ill medical patient
- efficacy
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Alikhan, R
-
Cohen, AT
-
Combe, S
-
Samama, MM
-
Desjardins, L
-
Eldor, A
-
visa fler...
-
Janbon, C
-
Leizorovicz, A
-
Olsson, Carl-Gus ...
-
Turpie, AGG
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Blood Coagulatio ...
- Av lärosätet
-
Lunds universitet